Cardiohepatic syndrome

Article written and reviewed by Dr Luca Moretti

Cardiohepatic syndrome describes the bidirectional interaction between cardiac disease and hepatic dysfunction. In heart failure, it primarily includes congestive hepatopathy due to chronically increased venous pressures and acute cardiogenic liver injury due to hypoperfusion, often overlapping in the same episode. The term must not obscure the etiology: right-sided failure, tricuspid regurgitation, pericardial disease, Fontan circulation, and shock produce different phenotypes; cirrhosis, steatohepatitis, and portopulmonary hypertension may, in turn, cause or aggravate cardiac dysfunction. Assessment must establish direction, severity, and reversibility; this distinction changes decongestion, valvular procedures, LVAD use, isolated or combined heart transplantation, and interpretation of common liver tests.

The liver receives a dual blood supply, is exposed to right atrial pressure through the hepatic veins, and has considerable reserve. For this reason, advanced congestion may produce modest biochemical abnormalities, whereas an acute reduction in flow causes centrilobular necrosis with markedly elevated aminotransferases. Elastography, scores, and biopsy are influenced by congestion and the uneven distribution of fibrosis; no single test always distinguishes reversible fibrosis from clinically significant structural cirrhosis. Management requires cardiology, hepatology, imaging, anesthesia, and transplant expertise when disease is advanced; control of cardiac disease is the central treatment, but must be balanced against perfusion, renal function, coagulation, and portal risk.

Etiology, pathogenesis, and pathophysiology

Congestive hepatopathy arises from a persistent increase in right atrial pressure, transmitted to the vena cava, hepatic veins, and sinusoids. Right ventricular failure, tricuspid regurgitation, pulmonary hypertension, and constrictive pericarditis are typical causes; congestion dilates the centrilobular sinusoids, causing local hypoxia, atrophy, and collagen deposition. Fibrosis extends between central veins with a reversed architecture compared with the portal-to-portal bridging of many primary liver diseases; the relationship between pressure, duration, and fibrosis is not linear. Repeated episodes of low cardiac output, inflammation, sinusoidal thrombosis, and individual vulnerability modulate progression.

Acute cardiogenic liver injury, often called hypoxic or ischemic hepatitis, results from a reduction in oxygen delivery. Shock, cardiac arrest, arrhythmia, pulmonary embolism, and respiratory failure are precipitants, but documented hypotension may be absent; preexisting congestion sensitizes zone 3 to reduced flow. AST and ALT rise rapidly, often above 1000 U/L, with elevated LDH and a subsequent increase in bilirubin and INR; the enzyme peak alone does not measure residual liver mass. If hemodynamics and oxygenation improve, aminotransferases fall within days; failure to decline requires investigation for persistent hypoperfusion, thrombosis, toxicity, viral hepatitis, or another cause.

In Fontan circulation, elevated systemic venous pressure and nonpulsatile flow cause liver disease from childhood. Fibrosis, regenerative nodules, portal hypertension, and hepatocellular carcinoma may develop despite nearly normal tests. FALD is a specific phenotype: elastography simultaneously reflects pressure and fibrosis, biopsy findings are heterogeneous, and thresholds derived from conventional cirrhosis are not automatically applicable. Arrhythmias, circuit obstructions, collaterals, and ventricular dysfunction accelerate injury. Hemodynamic optimization and liver surveillance continue throughout life.

Primary liver disease may affect the heart through splanchnic vasodilation, neurohormonal activation, and a hyperdynamic circulation; cirrhotic cardiomyopathy includes impaired contractile response, diastolic dysfunction, chronotropic incompetence, and electrical instability that emerge during stress. Portopulmonary hypertension increases right ventricular afterload, whereas hepatopulmonary syndrome causes vasodilation and hypoxemia. These are different entities with opposite transplant implications and require hemodynamic and respiratory assessment. Metabolic steatosis, alcohol, viruses, autoimmunity, and medications may coexist with heart failure; the presence of a cardiac explanation does not justify omitting a hepatological workup.

Ascites and edema result from sinusoidal pressure, renal sodium retention, RAAS, and vasopressin. In cardiac congestion, ascitic fluid typically has a serum-ascites albumin gradient of at least 1.1 g/dL and protein above 2.5 g/dL because sinusoidal permeability is preserved. With advanced cirrhosis, protein may decrease and the profile become mixed; intra-abdominal pressure further impairs renal perfusion, diuretic absorption, and venous return, linking the heart, liver, and kidney. Hyperbilirubinemia, hypoalbuminemia, and an abnormal INR reflect cholestasis, synthesis, nutrition, anticoagulants, and sepsis; their specificity is limited, but the trajectory retains prognostic value.

Clinical manifestations

Congestive hepatopathy may be silent or present with right epigastric heaviness, nausea, early satiety, and distension. Hepatomegaly, elevated jugular venous pressure, hepatojugular reflux, edema, and ascites indicate elevated systemic pressure; a pulsatile liver suggests significant tricuspid regurgitation. Kussmaul's sign, a pericardial knock, or respiratory discordance point to constriction or restrictive physiology. Mild jaundice is possible, but marked elevations require consideration of acute injury, sepsis, hemolysis, or obstruction. Splenomegaly and collaterals suggest more advanced portal hypertension.

In acute injury, the causal presentation predominates: shock, dyspnea, chest pain, arrhythmia, hypoxemia, or cardiac arrest. Upper quadrant pain may result from rapid capsular distension, but specific hepatic symptoms are often absent. Confusion may reflect hypoperfusion, sedatives, sepsis, uremia, or encephalopathy; an isolated blood ammonia level does not distinguish these causes and must not replace clinical examination. Hypoglycemia, persistent lactate elevation, and coagulopathy indicate severe impairment; prognosis depends primarily on cardiovascular reversibility and the number of organs involved.

Cardiac ascites tends to be associated with elevated jugular venous pressure and edema, but cirrhosis and heart failure may coexist. Right-sided hydrothorax, hernias, and malnutrition may occur in both and do not define the origin. Varices, thrombocytopenia, splenomegaly, and portosystemic collaterals indicate clinically significant portal hypertension, but in congestion absolute pressures may be high without a large gradient. Gastrointestinal bleeding may result from varices, angiodysplasias, anticoagulants, or ischemia. Stabilization and endoscopy must take limited cardiac reserve into account.

FALD may manifest with hepatomegaly, nodules, thrombocytopenia, ascites, varices, or carcinoma. Ascites in a Fontan patient may also indicate hemodynamic failure, protein-losing enteropathy, or obstruction, not only cirrhosis; low oxygen saturation, reduced capacity, and arrhythmias may signal circuit deterioration. The phenotype requires an adult congenital heart disease center and dedicated hepatic expertise. Hypervascular nodules are common and may mimic carcinoma; growth, washout, and multimodality imaging guide biopsy and surveillance.

Signs of primary liver disease include cutaneous stigmata, neuropathy, gynecomastia, xanthelasmas, pruritus, and a history of alcohol use, metabolic disease, or autoimmunity; their absence does not exclude compensated cirrhosis. In cirrhosis, dyspnea and intolerance may result from anemia, ascites, effusion, hepatopulmonary syndrome, or cardiomyopathy; orthodeoxia points toward intrapulmonary vascular dilations. Syncope, a pulmonary murmur, and right heart dilation suggest portopulmonary hypertension. Confirmation requires right heart catheterization, because echocardiography estimates but does not diagnose vascular resistance.

Investigations and diagnosis

The panel includes AST, ALT, alkaline phosphatase, GGT, total and direct bilirubin, albumin, INR, complete blood count, and renal function; patterns are interpreted with trends, anticoagulation, nutrition, hemolysis, and sepsis. Cholestasis and a modest aminotransferase increase predominate in congestion; AST, ALT, and LDH dominate in acute injury; a high LDH ratio and rapid decline support hypoxia but do not eliminate competing diagnoses. Viral studies, autoantibodies, immunoglobulins, iron, ceruloplasmin, or alpha-1-antitrypsin are requested according to age and context. Acetaminophen and other toxic agents are investigated when injury is severe.

Echocardiography assesses the right heart, tricuspid valve, vena cava, pulmonary pressures, left heart, and pericardium. Hepatic venous Doppler shows increased pulsatility and systolic reversal in severe regurgitation; the portal vein and renal veins document transmission of congestion. Liver ultrasound assesses morphology, flows, ascites, the spleen, and focal lesions. Hepatic vein dilation and retrograde contrast on CT support a cardiac origin, but a nodular surface alone does not prove irreversible cirrhosis. CT and magnetic resonance imaging characterize nodules, collaterals, and thrombosis; contrast is selected considering the kidney, instability, and actual clinical impact.

Elastography measures stiffness, which increases with both fibrosis and congestion; a reduction after decongestion demonstrates a hemodynamic component; a high value during overload must not automatically be converted into a fibrosis stage. MELD, MELD-Na, Child-Pugh, and simple indices are validated primarily in primary cirrhosis; MELD-XI, which excludes INR, is often used in anticoagulated patients with heart failure and provides prognostic information, but does not replace anatomical diagnosis. Platelets, albumin, and bilirubin are affected by hemodilution, nutrition, and medications. Discordant scores require review of their determinants.

Diagnostic paracentesis is indicated for new or worsening ascites or ascites in hospitalized patients. Cell count and culture exclude infection; the albumin gradient and protein distinguish mechanisms, with limitations in mixed phenotypes. Markedly elevated NT-proBNP in serum or fluid supports cardiac ascites; spontaneous bacterial peritonitis is less common in protein-rich fluid but must be investigated if neutrophils or the clinical presentation indicate it. Removal of large volumes changes preload and pressure. Albumin and monitoring are adapted to the etiology and volume, avoiding blind application of protocols.

Right heart catheterization measures right atrial, pulmonary artery, and wedge pressures and cardiac output and identifies constriction, portopulmonary hypertension, and procedural risk. HVPG may remain normal in noncirrhotic congestion because free and wedged pressures increase together; an elevated gradient suggests an acquired intrahepatic barrier. Transjugular biopsy allows sampling and pressure measurements with lower risk in coagulopathy, but fibrosis heterogeneity may cause error; the report must consider sinusoidal dilation, centrilobular necrosis, and bridging patterns. In LVAD or transplant candidates, the decision arises from the combined assessment of portal hypertension, imaging, synthesis, nodules, hemodynamics, and histology; no isolated cutoff automatically mandates a dual-organ transplant.

Treatment and prognosis

Treatment of congestive hepatopathy consists of reducing pressures by correcting heart failure. Loop diuretics, sequential blockade, and treatment that improves prognosis are titrated according to euvolemia, renal status, and blood pressure; disappearance of edema does not prove normalization of venous pressure. Tricuspid regurgitation, constriction, a shunt, or arrhythmia may require a specific intervention; effective decongestion often reduces bilirubin and stiffness, but excessive removal causes hypoperfusion and acute injury. Sodium, fluids, and nutrition are individualized. Severe restrictions may aggravate sarcopenia and do not replace an adequate diuretic strategy.

In acute cardiogenic injury, oxygenation, blood pressure, and cardiac output are restored and the cause is corrected. Revascularization, shock treatment, arrhythmia control, drainage for tamponade, or treatment of embolism take priority over nonspecific hepatic interventions. There is no antidote for hypoxic necrosis. N-acetylcysteine is essential in acetaminophen overdose and may be considered in selected cases of acute liver failure not caused by acetaminophen according to hepatology protocols, but does not replace hemodynamic recovery. Glucose, coagulation, encephalopathy, and infections are monitored. An abnormal INR without bleeding is not normalized indiscriminately, because plasma adds volume and does not correct synthesis.

Paracentesis relieves tense ascites and may improve renal perfusion and breathing; removal is coordinated with preload, albumin, and diuretics; recurrent ascites requires reassessment of the heart, adherence, and the portal component. TIPS reduces portal pressure but increases venous return and may precipitate right-sided failure. Severe right ventricular dysfunction, significant pulmonary hypertension, and uncontrolled heart failure are contraindications or major limitations and require a hemodynamic study. Nonselective beta-blockers for variceal prophylaxis may reduce reserve and blood pressure in advanced heart failure. The indication and dose are agreed upon by the hepatologist and cardiologist.

ACE inhibitors, ARNIs, beta-blockers, MRAs, and SGLT2 inhibitors are used according to cardiac phenotype and tolerance. In cirrhosis with ascites, vasodilation and AKI require particular caution with RAAS inhibition; the hepatic diagnosis changes safety considerations but does not create a single rule. Medications are dosed considering hepatic flow, albumin, renal status, and interactions; the label hepatotoxic does not justify automatic discontinuation: pattern, dose, alternatives, and necessity are assessed. Anticoagulation for atrial fibrillation, prosthetic valves, or thrombosis is individualized. INR in cirrhosis does not fully measure the balance between bleeding and thrombosis.

In advanced heart failure, an LVAD may reduce congestion and improve some parameters, but right ventricular dysfunction and cirrhosis increase bleeding, infection, and mortality. MELD-XI, hemodynamics, and portal signs contribute to selection; isolated heart transplantation may allow regression of congestion and some fibrosis. Heart-liver transplantation is considered when clinically significant cirrhosis, portal hypertension, or primary liver disease makes recovery unlikely, according to the center's criteria. In Fontan patients, the choice between isolated heart and combined transplantation is particularly complex. Nodules, portal hypertension, synthetic function, anatomy, and history are discussed in an experienced program.

The prognosis of acute injury is poor and depends primarily on shock and multiorgan failure; in-hospital mortality may approach half in the most severe cohorts. A rapid decline in aminotransferases does not guarantee survival if the circulation does not recover. In chronic congestion, bilirubin, albumin, MELD-XI, and stiffness are associated with outcomes but also reflect cardiac severity; an integrated prognosis considers renal status, the right heart, pulmonary pressure, nutrition, and frailty. Surveillance and advance decisions prevent a reversible condition from becoming a late contraindication. Palliative care is integrated when transplantation or support is not feasible.

Complications

Portal hypertension may cause varices, ascites, hypersplenism, and portal vein thrombosis. In pure congestion, the gradient may be low, but the appearance of collaterals suggests advanced remodeling or concomitant liver disease; variceal bleeding requires cautious resuscitation, portal vasoactive agents, an antibiotic, and endoscopy according to guidelines, with management coordinated around reduced cardiac reserve. Transfusion-associated overload worsens congestion; thrombocytopenia may result from splenic effects, medications, devices, or sepsis. The mechanism must be clarified before procedures or anticoagulation.

Encephalopathy may be precipitated by infection, bleeding, hypokalemia, constipation, sedatives, and renal failure. In patients with cardiac disease, hypoperfusion and delirium are competing diagnoses and require a multiparametric approach; hepatorenal syndrome occurs in cirrhosis with vasodilation and specific criteria; not every AKI in a congested patient is HRS. Albumin and vasoconstrictors without correct classification may worsen volume overload and afterload. Infections, peritonitis, and sepsis reduce vascular resistance and precipitate heart failure. Prompt cultures and antibiotics accompany cautious hemodynamic management.

Coagulopathy and thrombosis coexist because procoagulant and anticoagulant factors decrease differently. INR does not protect against thromboembolism and does not independently predict procedural bleeding; hemostatic management uses history, the procedure, platelets, fibrinogen, and viscoelastic tests when available. Plasma or concentrates are reserved for specific indications. Hepatic or portal vein thrombosis requires distinction from stasis and assessment of extent, tumor, and risk; anticoagulation depends on the context.

Advanced fibrosis and FALD increase the risk of hepatocellular carcinoma. Ultrasound and AFP according to risk are supplemented with CT or magnetic resonance imaging when nodules and anatomy reduce accuracy; congestive regenerative nodules may show arterial enhancement and mimic HCC. Growth, washout, capsule, and serial comparison are essential, with selected biopsy; surveillance is not discontinued after cardiac improvement if cirrhosis persists. Oncological risk depends on the residual structure.

Malnutrition, sarcopenia, and frailty worsen tolerance of interventions, LVADs, and transplantation. Ascites and edema distort weight and body mass index, whereas low albumin also reflects inflammation and dilution; nutritional assessment uses strength, mass, and intake in addition to liver tests. Protein is not routinely restricted for encephalopathy, except in specific temporary situations. Pruritus, cramps, sleep disturbances, and anxiety reduce quality of life; symptom control proceeds alongside causal and transplant decisions.